Asosiy kontentga oʻtish
AkademIndex

Xizmatlar

John J.V. McMurray

25 ta ish

University of Glasgow

AkademScholarda batafsil koʻrsatkichlar

  1. Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC.

    Theresa A. McDonagh, Theresa A McDonagh, Marco Metra +54

    Maqola202111 iqtibos
    ABI

  2. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)

    Authors/Task Force Members:, Joep Perk, Guy De Backer +82

    MaqolaOchiq kirish20126 iqtibos
    ABI

  3. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

    John J.V. McMurray, Scott D. Solomon, Silvio E. Inzucchi +35

    Maqola20196 iqtibos
    ABI

  4. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

    John J.V. McMurray, Milton Packer, Akshay S. Desai +8

    Maqola20146 iqtibos
    ABI

  5. 2013 ACCF/AHA Guideline for the Management of Heart Failure

    Clyde W. Yancy, Mariell Jessup, Biykem Bozkurt +21

    Maqola20136 iqtibos
    ABI

  6. Dapagliflozin in Patients with Chronic Kidney Disease

    Hiddo J.L. Heerspink, Bergur V. Stefánsson, Ricardo Correa‐Rotter +11

    Maqola20205 iqtibos
    ABI

  7. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

    Faı̈ez Zannad, John J.V. McMurray, Henry Krum +6

    Maqola20105 iqtibos
    ABI

  8. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

    Theresa A. McDonagh, Marco Metra, Marianna Adamo +94

    Maqola20214 iqtibos
    ABI

  9. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

    Paulus Kirchhof, Stefano Benussi, Dipak Kotecha +47

    Maqola20164 iqtibos
    ABI

  10. Current State of Knowledge on Aetiology, Diagnosis, Management, and Therapy of Peripartum Cardiomyopathy: A Position Statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy

    Karen Sliwa, Denise Hilfiker‐Kleiner, Mark C. Petrie +15

    Sharh maqolaOchiq kirish20103 iqtibos
    ABI

  11. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)

    Authors/Task Force Members, A. John Camm, Paulus Kirchhof +67

    Maqola20103 iqtibos
    ABI

  12. Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK

    Nathalie Conrad, Geert Verbeke, Geert Molenberghs +7

    MaqolaOchiq kirish20222 iqtibos
    ABI

  13. The burden of heart failure

    John J.V. McMurray, Simon Stewart

    Maqola20022 iqtibos
    ABI

  14. Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events

    John J McMurray, John J.V. McMurray, Steven M Haffner +51

    Maqola20102 iqtibos
    ABI

  15. The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data

    Raj Padwal, Finlay A. McAlister, John J.V. McMurray +13

    Sharh maqola20132 iqtibos
    ABI

  16. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

    Salim Yusuf, Marc A. Pfeffer, Karl Swedberg +6

    Maqola20032 iqtibos
    ABI

  17. Heart Failure and Chronic Obstructive Pulmonary Disease: Diagnostic Pitfalls and Epidemiology

    Nathaniel M. Hawkins, Mark C. Petrie, Pardeep S. Jhund +3

    Sharh maqola20092 iqtibos
    ABI

  18. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials

    John G.F. Cleland, Karina V Bunting, Marcus Flather +19

    Sharh maqola20172 iqtibos
    ABI

  19. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

    Scott D. Solomon, John J.V. McMurray, Inder S. Anand +31

    Maqola20192 iqtibos
    ABI

  20. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure

    Scott D. Solomon, Muthiah Vaduganathan, Brian Claggett +22

    Maqola20192 iqtibos
    ABI

  21. Ethnic-Specific Normative Reference Values for Echocardiographic LA and LV Size, LV Mass, and Systolic Function

    Katrina Poppe, R. Doughty, Julius M. Gardin +79

    Maqola20152 iqtibos
    ABI

  22. Seasonal variations in cardiovascular disease

    Simon Stewart, Ashley K. Keates, Adele L. Redfern +1

    Sharh maqola20172 iqtibos
    ABI

  23. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

    Paulus Kirchhof, Stefano Benussi, Dipak Kotecha +47

    Maqola20162 iqtibos
    ABI

  24. Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure

    Karl Swedberg, Faı̈ez Zannad, John J.V. McMurray +5

    Maqola20122 iqtibos
    ABI

  25. Iron deficiency: an ominous sign in patients with systolic chronic heart failure

    Ewa A. Jankowska, Piotr Rozentryt, Agnieszka Witkowska +10

    Maqola20102 iqtibos
    ABI